Sahajpal, N.S.; Mondal, A.K.; Singh, H.; Vashisht, A.; Ananth, S.; Saul, D.; Hastie, A.R.; Hilton, B.; DuPont, B.R.; Savage, N.M.;
et al. Clinical Utility of Optical Genome Mapping and 523-Gene Next Generation Sequencing Panel for Comprehensive Evaluation of Myeloid Cancers. Cancers 2023, 15, 3214.
https://doi.org/10.3390/cancers15123214
AMA Style
Sahajpal NS, Mondal AK, Singh H, Vashisht A, Ananth S, Saul D, Hastie AR, Hilton B, DuPont BR, Savage NM,
et al. Clinical Utility of Optical Genome Mapping and 523-Gene Next Generation Sequencing Panel for Comprehensive Evaluation of Myeloid Cancers. Cancers. 2023; 15(12):3214.
https://doi.org/10.3390/cancers15123214
Chicago/Turabian Style
Sahajpal, Nikhil Shri, Ashis K. Mondal, Harmanpreet Singh, Ashutosh Vashisht, Sudha Ananth, Daniel Saul, Alex R. Hastie, Benjamin Hilton, Barbara R. DuPont, Natasha M. Savage,
and et al. 2023. "Clinical Utility of Optical Genome Mapping and 523-Gene Next Generation Sequencing Panel for Comprehensive Evaluation of Myeloid Cancers" Cancers 15, no. 12: 3214.
https://doi.org/10.3390/cancers15123214
APA Style
Sahajpal, N. S., Mondal, A. K., Singh, H., Vashisht, A., Ananth, S., Saul, D., Hastie, A. R., Hilton, B., DuPont, B. R., Savage, N. M., Kota, V., Chaubey, A., Cortes, J. E., & Kolhe, R.
(2023). Clinical Utility of Optical Genome Mapping and 523-Gene Next Generation Sequencing Panel for Comprehensive Evaluation of Myeloid Cancers. Cancers, 15(12), 3214.
https://doi.org/10.3390/cancers15123214
